Relmada Therapeutics (RLMD) Change in Acquisitions & Divestments (2020 - 2026)

Relmada Therapeutics (RLMD) has 7 years of Change in Acquisitions & Divestments data on file, last reported at $14.3 million in Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments fell 9.83% year-over-year to $14.3 million in Q1 2026; TTM through Mar 2026 was $34.1 million, a 45.31% decrease from a year earlier, with the FY2025 full-year figure at $35.7 million, down 43.92% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $14.3 million, up from $5.9 million in the prior quarter.
• Over the last five years, Change in Acquisitions & Divestments for RLMD reached as high as $74.8 million in Q1 2023 and fell as low as $5.9 million in Q4 2025.
• Historically, Change in Acquisitions & Divestments has averaged $18.9 million across 5 years, with a median of $15.3 million in 2024.
• Across the five-year window, Change in Acquisitions & Divestments slumped 86.53% in 2022 and surged 517.79% in 2023, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $6.6 million in 2022, then jumped by 517.79% to $41.1 million in 2023, then tumbled by 70.77% to $12.0 million in 2024, then plunged by 51.2% to $5.9 million in 2025, then surged by 144.04% to $14.3 million in 2026.
• Per Business Quant data, the three most recent Change in Acquisitions & Divestments figures were $14.3 million in Q1 2026, $5.9 million in Q4 2025, and $7.0 million in Q3 2025.